Cargando…

Autoantibody Biomarkers in Rheumatic Diseases

Autoantibodies encountered in patients with systemic rheumatic diseases bear clinical significance as a biomarker to help or predict diagnosis, clinical phenotypes, prognosis, and treatment decision-making. Furthermore, evidence has accumulated regarding the active involvement of disease-specific or...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Eun Ha, Ha, You-Jung, Lee, Yun Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073052/
https://www.ncbi.nlm.nih.gov/pubmed/32085664
http://dx.doi.org/10.3390/ijms21041382
_version_ 1783506548701528064
author Kang, Eun Ha
Ha, You-Jung
Lee, Yun Jong
author_facet Kang, Eun Ha
Ha, You-Jung
Lee, Yun Jong
author_sort Kang, Eun Ha
collection PubMed
description Autoantibodies encountered in patients with systemic rheumatic diseases bear clinical significance as a biomarker to help or predict diagnosis, clinical phenotypes, prognosis, and treatment decision-making. Furthermore, evidence has accumulated regarding the active involvement of disease-specific or disease-associated autoantibodies in the pathogenic process beyond simple association with the disease, and such knowledge has become essential for us to better understand the clinical value of autoantibodies as a biomarker. This review will focus on the current update on the autoantibodies of four rheumatic diseases (rheumatoid arthritis, myositis, systemic sclerosis, and anti-neutrophil cytoplasmic antibody associated vasculitis) where there has been a tremendous progress in our understanding on their biological effects and clinical use.
format Online
Article
Text
id pubmed-7073052
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70730522020-03-19 Autoantibody Biomarkers in Rheumatic Diseases Kang, Eun Ha Ha, You-Jung Lee, Yun Jong Int J Mol Sci Review Autoantibodies encountered in patients with systemic rheumatic diseases bear clinical significance as a biomarker to help or predict diagnosis, clinical phenotypes, prognosis, and treatment decision-making. Furthermore, evidence has accumulated regarding the active involvement of disease-specific or disease-associated autoantibodies in the pathogenic process beyond simple association with the disease, and such knowledge has become essential for us to better understand the clinical value of autoantibodies as a biomarker. This review will focus on the current update on the autoantibodies of four rheumatic diseases (rheumatoid arthritis, myositis, systemic sclerosis, and anti-neutrophil cytoplasmic antibody associated vasculitis) where there has been a tremendous progress in our understanding on their biological effects and clinical use. MDPI 2020-02-18 /pmc/articles/PMC7073052/ /pubmed/32085664 http://dx.doi.org/10.3390/ijms21041382 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kang, Eun Ha
Ha, You-Jung
Lee, Yun Jong
Autoantibody Biomarkers in Rheumatic Diseases
title Autoantibody Biomarkers in Rheumatic Diseases
title_full Autoantibody Biomarkers in Rheumatic Diseases
title_fullStr Autoantibody Biomarkers in Rheumatic Diseases
title_full_unstemmed Autoantibody Biomarkers in Rheumatic Diseases
title_short Autoantibody Biomarkers in Rheumatic Diseases
title_sort autoantibody biomarkers in rheumatic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073052/
https://www.ncbi.nlm.nih.gov/pubmed/32085664
http://dx.doi.org/10.3390/ijms21041382
work_keys_str_mv AT kangeunha autoantibodybiomarkersinrheumaticdiseases
AT hayoujung autoantibodybiomarkersinrheumaticdiseases
AT leeyunjong autoantibodybiomarkersinrheumaticdiseases